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toledorodrigo79@gmail.comAbstractAccurate interpretation of germline mutations of the rearranged during transfection (RET)
proto-oncogene is vital for the proper recommendation of preventive thyroidectomy in
medullary thyroid carcinoma (MTC)-prone carriers. To gain information regarding the most
disputed variant of RET, ATA-A Y791F, we sequenced blood DNA samples from a cohort
of 2904 cancer-free elderly individuals (1261 via Sanger sequencing and 1643 via whole-
exome/genome sequencing). We also accessed the exome sequences of an additional 8069
individuals from non-cancer-related laboratories and public databanks as well as genetic
results from the Catalogue of Somatic Mutations in Cancer (COSMIC) project. The mean
allelic frequency observed in the controls was 0.0031, with higher occurrences in Central
European populations (0.006/0.008). The prevalence of RET Y791F in the control databases
was extremely high compared with the 40 known RET pathogenic mutations (PZ0.00003),
while no somatic occurrence has been reported in tumours. In this study, we report new,
unrelated Brazilian individuals with germline RET Y791F-only: two tumour-free elderly
controls; two individuals with sporadic MTC whose Y791F-carrying relatives did not show
any evidence of tumours; and a 74-year-old phaeochromocytoma patient without MTC.
Furthermore, we showed that the co-occurrence of Y791F with the strong RET C634Y
mutation explains the aggressive MTC phenotypes observed in a large affected family that
was initially reported as Y791F-only. Our literature review revealed that limited analysesKey Words
" multiple endocrine
neoplasias
" RET oncogene
" MEN2
" medullary thyroid carcinoma
" geneticsicensed under a Creative Commons
.0 Unported License.
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Research R A Toledo et al. MTC not related to RET Y791F 22 :1 66have led to the misclassification of RET Y791F as a probable pathogenic variant and,
consequently, to the occurrence of unnecessary thyroidectomies. The current study will have
a substantial clinical influence, as it reveals, in a comprehensive manner, that RET Y791F only
shows no association with MTC susceptibility.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
q 2015 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.Endocrine-Related Cancer
(2015) 22, 65–76IntroductionMEN2 (MIM #164761) is a dominantly inherited multi-
glandular tumour syndrome that presents with a high
penetrance of medullary thyroid carcinoma (MTC;
observed in virtually 100% of cases), phaeochromocytoma
(50%) and parathyroid adenoma and/or hyperplasia (20%)
(Eng et al. 1996). Germline gain-of-function mutations of
the rearranged during transfection (RET) proto-oncogene,
mostly occurring in exons 8, 10, 11, 13, 14, 15 and 16,
activate RET via autophosphorylation of the trans-
membrane receptor tyrosine kinase; these mutant
receptors are highly expressed in MEN2-related tissues,
leading to tumour growth. The International Consortium
on MTC of 1996 (Eng et al. 1996), the 2001 Consensus on
MENs (Brandi et al. 2001) and the updated American
Thyroid Association (ATA) Consensus on MTC (Kloos et al.
2009) recommend that individuals carrying a germline
disease-causing RET mutation should be subjected to early
prophylactic total thyroidectomy, which is currently the
only effective approach for preventing the progression of
MTC. For the purpose of molecular diagnosis and for
adequate surgical management of patients and their
relatives, it is crucial to know whether a RET gene variant
identified via genetic testing is a benign polymorphism, a
variant of unknown clinical significance or a pathological
disease-causing mutation (Toledo et al. 2006).
Biased genetic analyses of highly selected patients, in
addition to relatively small numbers of controls, may
result in a misunderstanding and misclassification of the
pathogenicity of rare variants of medically actionable
genes (Weber & Eng 2005). In this context, there is
currently a great debate in the literature regarding the
potential pathogenicity of the c.2372AOT Y791F variant
in exon 13 of RET (Berndt et al. 1998, Fitze et al. 2002,
2004, Gimm et al. 2002, Brauer et al. 2004, Plaza-Menacho
et al. 2007, Tamanaha et al. 2007, Vestergaard et al. 2007,
Eng 2010, Erlic et al. 2010, Cerutti & Maciel 2013,
Pe˛czkowska et al. 2013, Rich et al. 2014).
Recently, we described nine MEN2A families carrying
both the classical RET C634Y mutation and the RET Y791F
variant, which revealed a previously unrecognised role forY791F in the MEN2 syndrome. Although further analysis
is still needed, our results indicate that Y791F may modify
the effects of other concurrent RET mutations and may
therefore act as a modifier variant (Toledo et al. 2010).
However, the role of RET Y791F-only in MTC/MEN2-
related pathogenesis and susceptibility is currently a
matter of dispute (Vestergaard et al. 2007, Kloos et al.
2009, Eng 2010, Erlic et al. 2010, Rich et al. 2014 and
Supplementary References, see section on supplementary
data given at the end of this article).
The current study represents the largest analysis
focusing on the RET (ATA-A) Y791F variant performed to
date, including new data from Sanger and next-generation
sequencing analyses of 2904 healthy adult/elderly individ-
uals. We also accessed genetic and genomic findings from
multiple public databases, resulting in the analysis of a total
of 11 544 healthy individuals and 18 163 cancer samples.Subjects
Written informed consent was obtained from the
subjects, in accordance with the protocols approved by
the Institutional Review Board of each participating centre.Cohorts of new investigated controls
In this study, we report data from 2904 previously
uninvestigated individuals from three tumour-free adult/
elderly cohorts. The first cohort comprised 1261 healthy
adult/elderly Brazilians (54% females and 46% males),
with a mean age of 65.2 years. Blood DNA samples from
these individuals were subjected to Sanger sequencing
of RET exon 13 in our laboratory at the University of Sao
Paulo School of Medicine. This cohort included samples
from the School of Public Health of the University of Sao
Paulo and control samples from the Experimental Oncol-
ogy Laboratory (LIM-24) of the University of Sao Paulo
School of Medicine. The ethnicity of the tumour-free
adult/elderly subjects was 79% White/White Latino and
10% African and mixed Black/Caucasian.
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Research R A Toledo et al. MTC not related to RET Y791F 22 :1 67The second cohort has been designated the SABE60C
cohort and is a control group that was assembled and
subjected to whole-exome sequencing by the Human
Genome and Stem Cell Research Center (HUG-CELL) of
the University of Sao Paulo. SABE60C consists of
604 Brazilian individuals from Sao Paulo City (214 males
and 390 females), with minimum and maximum ages of
63.3 and 92.2 respectively, and an average age of 74.2G6.9
years. The majority of the individuals in this cohort
were White (57.62%), followed by mixed Black/Caucasian
(18.38%), Black (7.45%), Asian (1.99%) and Amerindian
(0.33%). Approximately 7% (6.62%) of the individuals
answered positively to belonging to another ethnicity,
and 7.62% did not answer this question.
The third cohort investigated in this study is the
T2D-GENES cohort, which comes from a large collabo-
rative study composed of 1039 completely sequenced
individuals. The primary focus of this study group is the
discovery of new genes associated with the development
of type 2 diabetes using the information provided by large
human pedigrees. Each sequenced pedigree contains
between 22 and 86 individuals distributed across three to
five generations. The sample population is composed of
Mexican–American (48.9% males) individuals living
in San Antonio, Texas (SATX), who are part of the large
San Antonio Family Study (SAFS) project, which has been
ongoing for more than 25 years, with a primary focus on
cardiovascular diseases.Public databases
Genetic and genomic data from the following non-tumour-
enriched public databases were accessed: i) the NHLBI GO
Exome Sequencing Project; ii) the database of single
nucleotide polymorphisms (dbSNP) of the National Center
for Biotechnology Information (NCBI), National Library of
Medicine and iii) Ensembl (European Bioinformatics
Institute, EBI, and European Molecular Biology Laboratory,
EMBL), from the Wellcome Trust Sanger Institute (WTSI).
The genotyping results for the 1000 European–American
controls reported by Erlic et al. (2010) were also included.
In addition, genetic and genomic findings from the
cancer-specific Catalogue of Somatic Mutations in Cancer
(COSMIC) database were also accessed, while variant
classifications were obtained from the databases of the
ARUP MEN2/RET program of the Department of Path-
ology, University of Utah (Margraf et al. 2009).
All of the data from the databases were obtained
between 20 July and 23 July 2014, and the websites for
each database are listed at the end of the article.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
q 2015 The authors
Printed in Great BritainLiterature review
The PubMed and Google Scholar databases were used for
the literature review. Space limitations prevented us from
providing more thorough coverage of the topic, and we
apologise to those whose work could not be cited.
An extended list of the studies on RET Y791F is included
as online supplementary data.Methods
DNA extraction, PCR and Sanger sequencing
Blood DNA was extracted using the salting out method
and a Qiagen kit (Qiagen). PCR amplification of RET exon
13 was carried out using 10 ng of gDNA and the following
primers: F: 5 0-AACTTGGGCAAGGCGATGCA-3 0 and R:
5 0-AGAACAGGGCTGTATGGAGC-3 0. The PCR products
were run on a 1% agarose gel, and specific 277 bp
amplicons (Supplementary Fig. 3, see section on supple-
mentary data given at the end of this article) were then
purified using the ExoSap-IT enzyme (USB Co., Cleveland,
OH, USA). BigDye Terminator v.3.1 cycle sequencing
(Applied Biosystems) was employed to sequence the
reaction products, and the samples were run on an ABI
Prism 3130xl – Genetic Analyzer (Applied Biosystems).Whole-exome and whole-genome sequencing
Whole-exome sequence data were generated using Agilent
SureSelect v2 technology for targeted exon capture, and
the obtained reads were aligned using the Burrows-
Wheeler Aligner (BWH) tool. Piccard was employed to
convert, sort and index the aligned data files; the sequence
quality scores were recalibrated using Genome Analysis
Toolkit (GATK); and annotation of the variants was
performed using Annovar.
Whole-genome sequencing (WGS) of 586 individuals
was performed externally by Complete Genomics, Inc.
(CGI, Mountain View, CA, USA) via a sequence-by-ligation
method. The paired-end sequencing reads (70 bp) were
mapped using the human reference genome (V 37.2), with
a mean coverage of 60!. Variant calling was performed
by CGI using version 2.0.3.1 of their proprietary pipeline.
The false discovery rate estimates for SNP calls on the CGI
platform ranged from 0.2 to 0.6%. The variant calls within
the WGS were processed using CGA Tools software
(version 1.5.0, build 31), made available by CGI. The
WGS information was employed together with the
pedigree information and a previously generated gen-
ome-wide association chip for effective imputation ofPublished by Bioscientifica Ltd.
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(Li 2010). The final sample comprised 1039 individuals
genotyped using nearly 23 million SNPs.Protein structure analysis
The structure of the RET receptor was generated based on
the crystal structure of the RET tyrosine kinase domain
bound to adenosine that has been recently deposited in the
RCSB-PDB protein databank (ID: 4CKJ, Plaza-Menacho
et al. 2014) and using the software program YASARA (Krieger
et al. 2009). The RET domains were determined using the
Conserved Domain Database (CDD), and a figure was
generated with DOG 2.0 (Ren et al. 2009).In silico pathogenic prediction
Four packages with different algorithms were used to
investigate the pathogenicity of RET Y791F in silico: SIFT;
PMUT; Align-GVGD; and POLYPHEN2 (the websites are
listed at the end of the article).Statistical analysis
Statistical analysis was performed by O Meirelles using
IBM SPSS (www-01.ibm.com/software/analytics/spss/).Results
RET Y791F in the tumour-free cohorts
The analyses of 22 138 alleles from the control subjects
revealed that Y791F is a very rare SNP, with a frequency that
varies greatly among the analysed populations (Fig. 1 and
Supplementary Table 1, see section on supplementary data
given at the end of this article). In accordance with an initial0.009
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Figure 1
RET Y791F frequencies in different control populations/cohorts. The
highest frequencies are observed in the populations from central Europe,
especially Germany. Details of the populations are provided in
Supplementary Table 1.
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American cohorts of control individuals presented the
highest frequencies, which ranged from 0.0017 to 0.008.
The three Latincohorts togetherwith the African–American
population presented the lowest frequencies of RET Y791F,
ranging from 0 to 0.0007 (Supplementary Table 1). Notably,
both the original Y791F MTC cases reported by Berndt et al.
(1998) and the screen of 1000 controls conducted by Erlic
et al. (2010), which identified the highest allelic frequency
among the controls, are from Germany. In addition, as
discussed later in this study, the largest cohort of patients
carrying the Y791F variant also comes from Germany,
indicating a probably higher prevalence of the Y791F
variant in this country. Interestingly, one of the healthy
Y791F-only Brazilian individuals reported in this study and
the two unrelated Brazilian cases with sporadic MTC who
also carried the variant (descriptions of these individuals are
provided later in this report) were direct descendants of
Germans. In addition, at least two out of the nine Brazilian
MEN2A families with C634Y/Y791F that we had previously
reported were of German descent (Toledo et al. 2010,
Valente et al. 2013). However, no cases harbouring
C634Y/Y791F have been reported outside of Brazil thus far.
Owing to possible incomplete assessment of the
phenotypic features of affected individuals or late disease
onset, the control databases may conceivably include
patients with rare diseases such as (familial) MTC and
MEN2 syndrome who carry pathogenic RET variants. To
explore the chance of this situation occurring, we assessed
whether the Exome Sequencing Project (ESP) exome
variation database (which is not a tumour-enriched data-
bank) included any classical disease-associated RET
mutations. No alleles corresponding to strong RET
mutations, classified as an MTC level-3 risk by the consensus
on MENs or as levels C-D by the ATA MTC guidelines, were
foundin theESPcontroldatabases (Fig. 2 and Supplementary
Fig. 1, see section on supplementary data given at the end of
this article). Notably, one allele of the low-risk V804M
mutation, which is classified as MTC risk 1/ATA-A, was found
among the 13 000 RET alleles from the ESP database. Valine
804 is a gatekeeper residue that is critical for ATP binding and
activation of the RET kinase receptor. Protein conformation
analyseshave revealed that theV804MandV804Lmutations
modify the ATP-binding pockets of RET, facilitating ATP
binding and conferring resistance to the multikinase
inhibitor vandetanib, which is approved for the treatment
of advanced MTC (Carlomagno et al. 2004, Wells et al. 2010).
The identification of heterozygous RET V804M in the
controls may be due to the relatively mild phenotype or
late onset of MTC that is frequently associated with thisPublished by Bioscientifica Ltd.
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Figure 2
No RETATA-B, C or D alleles were found in the ESP control databases. Only
one instance of the V804M allele (ATA-A) was found among the 13 000
sequenced alleles, indicating a very low frequency of bona fide MTC-
related RET mutations in healthy individuals. In contrast, 15 alleles of Y791F
were found within the ESP control databases, indicating that the
frequencies of this specific variant behave differently, possibly as an
accompanying genetic modifier or as a benign polymorphism.
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Research R A Toledo et al. MTC not related to RET Y791F 22 :1 69variant (Feldman et al. 2000). The ESP dataset also included
one allele of each of the three RET variants G321K, K666E,
and R866W. These three last variants are very rare and are
noted on the ATA guidelines as ‘mutations based on limited
families/case reports and may representvariants of unknown
significance’ (Kloos et al. 2009).
In contrast to the absence/very low frequency of bona
fide RET-activating mutations in the ESP dataset, the
Y791F variant was present in 14 individuals, one of
whom was homozygous (N allelesZ15). This allelic
frequency is significantly higher than that observed
among the remaining RET mutations (PZ0.00003).Previously unreported tumour-free elderly individuals
harbouring RET Y791F
In this study, we report two BrazilianRETY791F carrierswho
were identified during the genetic screening of the healthy
elderly controls by Sanger sequencing performed in our
laboratory. The first subject is a 76-year-old woman who has
never developed tumours and presents no health compli-
cations. She has been followed by the Hospital das Clı´nicas
in Sao Paulo (HC-FMUSP) for routine check-ups. Her
calcitonin level was undetectable (!2 pg/ml) in September
2014, and she reports no history of tumours in her family.
Her father was German and died at the age of 75 due to a
heart attack. Her 45-year-old daughter (an only child) was
invited to come to the hospital to provide blood forhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
q 2015 The authors
Printed in Great Britainbiochemical examinations and genetic testing; her calcito-
nin level was !2 pg/ml, and sequencing analysis revealed
that she harboured the WT allele.
Less information is available regarding the second
subject with RET Y791F. She was also followed by
HC-FMUSP for routine check-ups, and her medical report
shows no tumour development or presence of other
serious clinical features. She died in 2008 at the age of 94.
In accordance with our data on elderly individuals
carrying RET Y791F without any history of tumours, a
recent study that analysed the exome data of 44
centenarian Ashkenazi Jews has found two individuals
(2/44Z0.045) harbouring the RET Y791F variant
(Freudenberg-Hua et al. 2014).Evaluation of RET Y791F in MTC, MEN2, hyperpara-
thyroidism (HPT) and phaeochromocytoma shows no
association with susceptibility to endocrine neoplasia
Berndt et al. (1998) first reported the presence of the Y791F
variant in MTC patients in 1998. In addition to the
mutational hotspots in exons 10 and 11, the authors
reported exon 13 as a new potential hotspot following the
identification of the L790F and Y791F variants in patients
with familial MTC. In the original paper, the two RET
Y791F families were small and included a combined total
of only three clinically affected individuals (Berndt et al.
1998). The association linking Y791F to familial
MTC/MEN2 is based on limited and selected cohorts.
More importantly, there is no convincing data in the
literature showing co-segregation of Y791F with MTC
(Supplementary References).
Additionally, Gimm et al. (2002) analysed German
patients with mutations in codons 790 and 791 and
suggested a mild form of the disease.
Through a review of the literature, we found two large
families reported to carry RET Y791F; one family is from
Denmark with Central Europe descendants, and the other
is from Brazil. Vestergaard et al. (2007) initially identified
a Danish young case with goitre carrying RET Y791F and
subsequently performed genetic screening of a total of 27
family members. It is noteworthy that 15 of the family
members were Y791F carriers, and none exhibited
abnormal clinical or biochemical results. The calcitonin
levels of the carriers and non-carriers in this family did not
differ significantly, and total thyroidectomy was post-
poned (Vestergaard et al. 2007). The second kindred were
a large Brazilian RET Y791F family with 17 carriers, ten of
whom were diagnosed with MTC, including cases with the
early and aggressive phenotype (Tamanaha et al. 2007).Published by Bioscientifica Ltd.
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only family, a subsequent analysis indicated that these
patients also harboured the bona fide activating germline
RET C634Y mutation (Cerutti & Maciel 2013, Valente et al.
2013). These results are in accordance with the previous
report of C634Y-Y791F cis being found in four Brazilian
MEN2A families (Toledo et al. 2010).
The largest reported cohort of patients carrying RET
Y791F was described by Frank-Raue and colleagues and
comprised 22 German MTC/MEN2 cases and 34 screened
relatives. The authors concluded that Y791F carriers
develop milder clinical features and achieve higher cure
rates compared with carriers of the codon 790 and 804
mutations (Frank-Raue et al. 2008). No control samples
from the German population were analysed in this study.
Patients with Y791F who display hyperparathyroidism
and no MTC have been reported as well (Vierhapper et al.
2005). Another study identified RET Y791F in German
patients with glioblastoma multiforme and gastric and
pancreatic cancers who showed no clinical features of
MTC or MEN2 (Ru¨ckert et al. 2011).
In accordance with the results of studies by Erlic et al.
(2010) and Pe˛czkowska et al. (2013) showing occasional
phaeochromocytoma cases with co-occurrence of the RET
Y791F variant and pathogenic variants in other phaeo-
chromocytoma-related genes, we identified a 68-year-old
male with phaeochromocytoma carrying the RET Y791F
variant and the new germline variant D236N in the SDHB
gene. Nevertheless, the pathogenicity of the latter variant
is still uncertain.Two new MTC patients harbouring RET Y791F without
a family history of endocrine neoplasias
In this study, we report a 37-year-old female followed by the
MEN clinic of the Federal University of Sao Paulo (UNIFESP)
who presented a thyroid nodule with cytological results
indicative of Hu¨rthle cell neoplasm and an extremely high
calcitonin level (2079 pg/ml, normalZ8.5/5.0 pg/ml).
During physical examination, the patient showed no
cutaneous lichen amyloidosis, marfanoid habitus or
mucosal neuromas. She underwent total thyroidectomy
with prophylactic central neck dissection. A pathological
analysis revealed a 2.5 cm MTC on the left thyroid lobe and
lymphocytic thyroiditis with clusters of hyperplastic
Hu¨rthle cells. The tumour was confined to the thyroid,
and the 20 lymph nodes that were analysed showed no
evidence of metastasis. A genetic analysis of all of the RET
hotspot exons revealed the Y791F variant. Three years after
surgery, the calcitonin levels of this patient remainhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
q 2015 The authors
Printed in Great Britainundetectable (!2 pg/ml); her carcinoembryonic antigen
(CEA) level was 1.6 ng/ml, and cervical ultrasonography
showed no sign of relapse. Additionally, her clinical and
biochemical screening results were negative for phaeo-
chromocytoma and hyperparathyroidism.
Screening of this patient’s family revealed no history of
endocrine tumours. Her 32-year-old sister also carries the
RET Y791F variant and presented a thyroid ultrasound
exhibiting thyroiditis and no nodules and biochemical
examinations showing no evidence of MTC (calcitonin
levels!1 pg/ml) or primary hyperparathyroidism. She was
followed by another service and inadvertently underwent
thyroidectomy. Pathological analysis found no evidence of
MTC or C-cell hyperplasia. Her mother (59 years old) and
her two sons (18 and 11 years old) did not harbour the RET
Y791F variant and presented low calcitonin levels. Her
father, who was probably theobligatory carrier, died in a car
accident at the age of 46 years with no signs of the disease.
He was from Germany. The lack of a family history of MTC
in this family with three carriers argues that the RET Y791F
variant is not an endocrine-neoplasia-susceptibility
variant. Unfortunately, similar to this family, other
asymptomatic relatives with the Y791F variant have also
undergone unnecessary thyroidectomies (Supplementary
References).
Recently, we have identified another patient with
MTC harbouring the RET Y791F variant from the city
of Curitiba, Brazil. The patient, a 35-year-old woman, was
diagnosed with a thyroid nodule. The patient underwent
a thyroidectomy, and the final histological analysis
revealed MTC. An extended RET analysis (exons 1–12
and 14–21) was performed, and no other mutations were
identified. The patient has a 9-year-old daughter exhibit-
ing normal thyroid ultrasound results. The patient also has
a German background.A new elderly phaeochromocytoma patient harbouring
RET Y791F without MTC
A RET Y791F germline variant was observed in a patient
being followed at Santa Casa Hospital in Sao Paulo, who
was referred to our laboratory for genetic testing at the
University of Sao Paulo. The remaining RET hotspot exons
were sequenced, and no variant was identified. The patient
was a 74-year-old man diagnosed with a left adrenal
incidentaloma (9!8.3!6.5 cm). He had shown hyperten-
sion for the past 14 years, in addition to exhibiting chronic
atrial fibrillation and subclinical autoimmune hyper-
thyroidism. His surgical pathology was diagnostic of
phaeochromocytoma (8.5 cm and 220 g), and the resultsPublished by Bioscientifica Ltd.
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Research R A Toledo et al. MTC not related to RET Y791F 22 :1 71of his thyroid ultrasound examination were compatible
with thyroiditis without nodules. His calcitonin and
calcium/parathyroid hormone levels were normal. No
family history of tumours was reported, and the sequencing
results for the TMEM127 gene showed no mutations. This
case is another example of an elderly individual harbouring
the RET Y791F variant without any increased risk for MTC.RET Y791F in human tumours
The number of RET ATA mutations observed in the
COSMIC genetic and genomic dataset increased substan-
tially according to the mutation’s aggressiveness: 94.1% of
the ATA RET mutations occurring in cancers belong to the
ATA C–D classification (strong mutations), while only 1.4%
are weak ATA-A RET mutations (Fig. 3 and Supplementary
Tables 2 and 3, see section on supplementary data given at
the end of this article). Among the ATA-A risk mutations,
the most common variant is V804M, while the remaining
variants are very rare and with an uncertain functional
effect according to the ATA classification.
Among the entire COSMIC dataset of 18 163 tumour
samples with available RET genotypes, only one
(a lymphoid neoplasm, ID: COSM1159820) presented the
RET Y791F variant (0.002% – no information available500
ATA classification RET mutations on COSMIC
8 (1.4%)
26 (4.5%)
64 (11.2%)
474 (82.9%)
572
ATA-A
ATA-B
ATA-C
ATA-D
Total
400
300
200
100
0
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Figure 3
The number of RET mutations observed in the COSMIC cancer genetic and
genomic dataset increases substantially according to the ATA mutation
aggressiveness classification: 94.1% of the RET mutations found in cancers
belong to the ATA C–D classification (strong mutations), while only 1.4%
consist of weak ATA-A RET mutations. One of the 8 (12.5%) ATA-A variants
is Y791F, corresponding to 0.17% of the mutations.
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
q 2015 The authors
Printed in Great Britainregarding somatic or germline status). Of the 1549 MTCs in
the COSMIC dataset, 625 (40.3%) exhibited a RET
mutation, none of which were Y791F, indicating that
there is not a frequent association between this variant and
MTC tumourigenesis (Supplementary Table 4, see section
on supplementary data given at the end of this article).
In addition to the lack of evidence regarding a ‘driver’
property of RET Y791F in human tumours, two reports
describing results indicative of a ‘passenger’ role for Y791F.
The first case is an Y791F MTC patient in whom the most
aggressiveRETmutation, M918T, was identified somatically,
which is most probably the cause of MTC (Fitze et al. 2002).
The second case has been recently reported by Carlino et al.
(2014) who described a patient with pancreatic carcinoma
presenting the typical KRAS G12D mutation and the RET
Y791F variant. There is no information as to whether the
Y791F mutation was germline or somatic in this patient, but
as KRAS G12D is a very well-described pancreatic cancer-
driver mutation, the results strongly indicate a minor/
non-pathological role for RET Y791F. Interestingly, the
patient is Caucasian, was born in Australia and has
a German surname (Carlino, electronic communication).RET Y791F in HSCR
RET Y791F was first described in a case of Hirschsprung’s
disease (HSCR) (Seri et al. 1997). HSCR is a genetically
heterogeneous disorder, and inactivation (nonsense and
frameshift) mutations in RET are its primary cause (Edery
et al. 1994). In families harbouring activating RET
mutations occurring primarily in extracellular domains
(i.e. exon 10), such as C620R, it has been classically
reported that HSCR develops in up to 7% of carriers. Since
the initial report, other Y791F-carrier HSCR cases with
no evidence of MTC have been reported, raising the
question as to whether this variant is actually involved
in tumourigenesis (Virtanen et al. 2013).In silico RET Y791F analyses
All four of the software programs used in this study
predicted low or very low pathogenicity for the RET Y791F
variant (data not shown). Although the software programs
employ different algorithms to calculate potential patho-
genicity, they all use evolutionary conservation, which
indicated that an amino acid change at Tyrosine 791 is
more likely to be tolerated, rather than being lethal or
pathogenic. Our assessment of the RET protein structure
indicate that Y791F localises to the N-lobe, in b 4, and is
close to the ATP-binding site (Supplementary Fig. 3),Published by Bioscientifica Ltd.
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RET mutations.In vitro RET Y791F assays
Plaza-Menacho et al. (2007) investigated the RET Y791F
variant in vitro and reported ligand-independent acti-
vation. According to the results of this previous study,
Y791F is an autophosphorylated monomeric activated
receptor that leads to the constitutive activation of STAT3.
However, the mechanism of STAT3 activation occurs via
Src, JAK1 and JAK2, which differs from the classical RET
C634R activation mechanism (Plaza-Menacho et al. 2007).
In a later study, Hyndman et al. (2013) analysed in vitro
RET variants that had been previously reported in HSCR
cases and showed that Y791F behaved similarly to the WT
protein in many respects, with similar RET/pERK/pSTAT3
phosphorylation, surface localisation, and RNA and protein
stability being observed. Nevertheless, unlike to the RET WT
protein and similarly to other HSCR variants, Y791F was
associated with reduced levels of cell migration and no
ability to promote colony formation (Hyndman et al. 2013).
Although this last study did not include bona fide RET-
activating mutations for comparison, the results indicate
WT-like functional and molecular effects of Y791F, rather
than Y791F acting as a gain-of-function mutation.
A third study by Cosci et al. (2011) combined in silico
and in vitro assays to analyse known pathogenic mutations
of RET, such as C634R and M918T and ‘rare medium/low-
risk’ variants, including Y791F. Correlations between the
results obtained using different approaches were observed
primarily for the stronger variants, while the overall
results and classification of the weaker variants remained
unclear. The in silico classification of RET Y791F was
deleterious, although focus and soft agar assays indicated
Y791F to be a weak and probably non-pathogenic
variant (Cosci et al. 2011). In contrast, the high prolife-
ration rates associated with Y791F, C634R and M918T
achieved statistical significance, but these results were
inconclusive, as several probably non-pathogenic variants,
such as V648I, also achieved statistical significance.
The three studies of RET cited above, together with
many others in the literature, show how difficult and
sometimes capricious it can be to characterise a weak
variant using in vitro or in silico approaches, especially in
genes related to genotypes with major medical impli-
cations, such as the recommendation for total thyroid-
ectomy in the case of RET. To the best of our knowledge,
there is no animal model of the RET Y791F variant.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
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in cases with pathogenic RET mutations
The data that we were able to generate and review in the
current study indicate a clear lack of pathogenicity of RET
Y791F-only. However, the possible role of Y791F as a
phenotype-modifying variant cannot be discarded. In fact,
we have recently reported four MEN2A families carrying
the classical RET C634Y mutation and Y791F in cis (Toledo
2010). The patients presented aggressive MTC (codon
C634-like pattern) associated with an increased suscep-
tibility to unusually large bilateral phaeochromocytomas.
This finding is indicative of a modifier effect of Y791F
when associated with classical disease-causing RET
mutations (Toledo 2010). In the same study, we described
in vitro analyses performed in Dr Lois Mulligan’s laboratory
(ON, Canada), demonstrating that the double C634Y/
Y791F RET receptor is significantly more highly phos-
phorylated than either the WT receptor or the single
C634Y and Y791F RET mutants (Toledo et al. 2010).
Interestingly, an association between RET C634Y and
Y791F has been recently observed in five additional Brazilian
families (Cerutti & Maciel 2013, Valente et al. 2013). In
addition to C634Y/Y791F, the presence of Y791F has been
reported in patients harbouring other disease-associated
RET mutations, such as C620F, V804L and M918T
(Jindrichova et al. 2004). Although current knowledge
shows no relevant clinical effect, the possible mechanism
of such co-occurrence seems worth exploring in the future.Known RET missense variants identified through
whole-exome/genome sequencing
Four variants classified as ATA-A mutations (S649L,
V804M, R844Q and S891A) (Kloos et al. 2009) were rarely
found in the whole-exome/genome sequences of the
tumour-free individuals assessed in the current study.
The V804M and S891A variants are also included in the
RET list as MTC level 1 mutations (Brandi et al. 2001). As
mentioned earlier, V804M is a well-described gatekeeper
mutation associated with a mild, late-onset phenotype,
which could explain its rare occurrence in the presumably
healthy cohort (1/13 000 alleles in the ESP dataset,
0.00007). The frequencies of V804M and Y791F in the
controls were very different and were compatible with a
true, low-risk mutation and a rare non-pathogenic variant
respectively (Fig. 2 and Supplementary Fig. 2, see section
on supplementary data given at the end of this article). In
addition, a novel change involving Valine 804 (c.2411COT;
p.V804A) was, to the best of our knowledge, identifiedPublished by Bioscientifica Ltd.
Table 1 The nine new variants of the RET proto-oncogene identified via whole-exome and whole-genome sequencing in the
current study
Casuistic Nucleotide Codon RET protein dbSNP or ESP SIFT PolyPhen2 n
Genotype
frequency
SABE60C C1352T 451 T451M* Not reported D B 1 0.0008
SATX T1418A 473 L473Q Not reported D D 3 0.0014
SATX A1462T 488 T488S Not reported T B 1 0.0004
SABE60C C1573T 525 R525W Not reported D D 1 0.0008
SABE60C C1678T 560 P560S Not reported D D 1 0.0008
SABE60C G1799T 600 R600L Not reported D B 1 0.0008
SATX C2077T 693 R693C Not reported D D 2 0.0001
SABE60C C2225T 742 T742M Not reported D D 1 0.0008
SABE60C A2255G 752 Y752C Not reported T D 1 0.0008
SATX T2411C 804 V804A Not reported D D 1 0.0005
Please see the discussion and interpretation of these findings in the main text. The T451M variant is not present in the control databases (dbSNP and ESP),
but it was identified in two endometrium carcinomas (COSMIC project IDs: 1584958 and 918112). The other variants have not been reported in COSMIC.
D, damaging; B, benign; T, tolerated; SABE60C, University of Sao Paulo; SATX, San Antonio, Texas.
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of 0.00001 in the SATX control cohorts). An in silico
analysis using both SIFT and Polyphen2 indicated the
V804M and V804A changes to be pathogenic.
In accordance with our results for S649L, seven
individuals from the ESP dataset were also identified as
harbouring this variant, which has been presumably
associated with late-onset, non-aggressive MTC (Colombo-
Benkmann et al. 2008).
RET V292M was also found in the SABE60C cohort
(1 out of 1218 of the sequenced alleles, 0.0008). This
variant is classified as pathogenic in the ARUP MEN2 and
dbSNP/NCBI databases, but it has not been included in the
MTC guidelines (Eng et al. 1996, Kloos et al. 2009).
Currently, limited evidence is available regarding the
pathogenicity of this variant.
The previously reported RET Y791N variant was
identified in two control individuals analysed via Sanger
sequencing (2/2522, 0.008): a 76-year-old male and a
55-year-old female. There is no evidence of pathogenicity
of this variant in the literature; it was initially reported
in a case of HSCR and later in the sister of an MTC case
harbouring RET R770Q (Ruiz-Ferrer et al. 2006, Frank-Raue
et al. 2010).Novel RET missense variants identified via
whole-exome/genome sequencing
Nine of the RET missense variants identified herein via
massive parallel DNA sequencing have not been reported
in the dbSNP/NCBI or ESP databanks and, to the best of
our knowledge, are novel (Table 1). Eight of the variants
were classified as damaging by Polyphen2 or SIFT; six werehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
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Printed in Great Britainclassified as damaging by both software programs; and
one variant was classified as benign/tolerated by both
software programs (Table 1). Despite the rarity of these
variants and the in silico predictions, the fact that our
population was composed of healthy adult/elderly indi-
viduals with no familial history of tumours indicates that
these variants are probably benign polymorphisms or low-
penetrance genetic changes. If new evidence appears in
the future indicating pathogenicity in these variants,
especially V804A, which occurs at a known RET hotspot,
we will contact the carriers and offer genetic counselling,
molecular testing and specific clinical screening.Conclusions of the current comprehensive
assessment of RET Y791F
1. There is no robust evidence from either our data or
the literature indicating that RET Y791F-only may
cause familial MTC or MEN2 syndrome (reports
addressing very small families should not be
considered to be informative). RET Y791F, like other
non-pathogenic variants of RET, can be found in
sporadic MTC patients, but its presence alone does
not indicate an increased MTC risk.
2. The frequencies of the RET Y791F variant detected in
large cohorts of healthy individuals are characteristic
of the behaviour of a rare benign polymorphism,
rather than a medically actionable pathogenic
mutation of the RET proto-oncogene.
Lessons from findings 1 and 2:
† Asymptomatic germline RET Y791F-only carriers
(with no other disease-causing mutations of RET)
should not undergo preventive total thyroidectomyPublished by Bioscientifica Ltd.
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comes, and biochemical and imaging data are the
most valuable resources for managing these cases.
† There is no indication that genetic and clinical
screening of family members of typical sporadic
MTC cases harbouring RET Y791F-only is beneficial.
3. The patients with familial MTC/MEN2 who were
initially reported to be RET Y791F-only carriers were
also found to harbour other associated disease-causing
RET variants (C634Y in cis), leading to the disease.
Lessons from finding 3:
† Genetic testing for RET is only complete when
sequencing of all of the hotspot mutations in
exons 8 and 10–16 is successfully performed. That
is, sequencing of the remaining exons should not
cease when the first suspect variant is identified.
† Sequencing or re-sequencing of the hotspot exons of
the RET gene (and possibly the full gene depending
on the phenotype) of familial MTC/MEN2 patients
initially described as RET Y791F-only carriers can
reveal medically actionable pathogenic mutations
in the RET proto-oncogene.
† Limitations of PCR, such as allelic drop-out (PCR
failure of one allele) and/or preferential amplifi-
cation (hypo-amplification of one allele), may be
responsible for false-negative RET genetic results.
Therefore, the use of a second set of primers (with
different sequences than those used for the initial
PCR and sequencing run) is recommended for the
re-sequencing of questionable cases.
4. Phaeochromocytoma patients initially reported to be
RET Y791F-only carriers can harbour variants of other
genes, e.g. VHL or SDHx, that are most probably the
cause of the disease.
Lesson from finding 4:
† Established clinical predictors and algorithms
should be used to sequence phaeochromocytoma-
susceptibility genes in phaeochromocytoma cases
that are initially reported as RET Y791F-only.
5. Biased genetic analysis of highly selected patients and
a relatively small number of controls can result in
misunderstanding and misclassification of the patho-
genicity of rare variants in medically actionable genes.
Lesson from finding 5:
† The analysis of large and informative datasets from
tumour-free individuals constitutes an accessible
and useful tool for improving the interpretation
of a molecular diagnosis and aiding in genetic
counselling and the clinical management and
treatment of carriers.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-14-0491
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Printed in Great BritainFinal comments about the era of NGS
The scientific and medical community working on RET-
related diseases needs to be aware of the implications
related to the dramatic increase in the number of new
variants of this gene being identified in the current next-
generation sequencing era. In fact, nine new RET variants
were identified in the present study. Moreover, it is
imperative to use caution when interpreting genetic
variants with limited information. At the same time,
access to genetic data from large cohorts presents an
opportunity to re-evaluate the clinical behaviour of
disputed RET variants, such as Y791F.Websites
1. NHLBI ESP Exome Sequencing Project: http://evs.gs.
washington.edu.
2. dbSNP/NCBI: http://www.ncbi.nlm.nih.gov/SNP.
3. Ensembl EBI/EMBL/WTSI: http://www.ensembl.org.
4. COSMIC: http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic.
5. ARUP RET database, Univ. Utah: http://arup.utah.
edu/database/MEN2/MEN2_display.php.
6. SIFT: sift.jcvi.org.
7. PMUT: http://mmb2.pcb.ub.es:8080/PMut/.
8. POLYPHEN2: http://genetics.bwh.harvard.edu/pph2/.
9. Align-GVGD: http://agvgd.iarc.fr/.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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